pharmaceutical investing Vertex Announces Northern Ireland Offer Accepted for Cystic Fibrosis Treatments
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis
NextSource Materials Signs Agreement for the Supply of Graphite Fines as Additional Source of Feedstock for its Battery Anode Facility in Abu Dhabi
